معرفی
Sunil Sharma is an Adjunct Professor in Molecular Pharmaceutics at the University of Utah. His research focuses on developing novel therapeutic strategies for cancer, particularly in colorectal, pancreatic, and hematologic malignancies. He leads clinical trials investigating combination therapies targeting immune checkpoints, ENPP1 inhibition, and CDK7 pathways. His work emphasizes overcoming treatment resistance through multi-agent regimens and preclinical models.
Research Interests:
- Cancer Immunotherapy
- ENPP1/STING Pathway Modulation
- Targeted Therapies for Solid Tumors
- Combination Therapy Development
- Preclinical Drug Efficacy Testing
Articles Trends: Recent work highlights Phase 1/2 trials of SR-8541A (ENPP1 inhibitor), CDK7 inhibitors (e.g., TGN-1062), and novel agents like RMC-6236. Studies emphasize synergy with existing therapies like checkpoint inhibitors and venetoclax, focusing on tumor microenvironment modulation and resistance mechanisms.
Grant & Advising: Collaborates with institutions like AACR and NIH on translational oncology projects. Advises on drug development pipelines and preclinical-to-clinical transitions.
Labs/Teams: Active in interdisciplinary teams exploring precision medicine, including the PATRIOT platform for personalized therapy predictions and neoantigen vaccine development.
